BioGenCell

Company Overview

Snapshot

Founded in December 2008 by Yael Porat, Eyal Peleg, and Michael Belkin, BioGenCell operates with 11–50 employees. The company has secured funding across four rounds from Marius Nacht and Michael Dezer. In May 2022, BioGenCell raised a Seed round led by Marius Nacht.

Business overview

BioGenCell is a Health Tech & Life Sciences company developing cellular therapies for degenerative diseases, focusing on blood flow problems in the limbs caused by diabetes and heart disease. The company's core technology creates autologous cells derived from patients to facilitate self-repair. Its lead product, BC1, targets blood vessel insufficiency in diabetic patients. BioGenCell's patented platform supports rapid manufacturing and long-term storage of therapeutic cellular products, aiming to treat a range of conditions including diabetes, heart failure, stroke, blindness, cancer, and immunological diseases. The company operates within the Pharma & Medical Biotechnology sector, specifically Drugs Discovery & Development, and serves healthcare providers, patients, and laboratories.

Strategic signal

In December 2024, BioGenCell received FDA Fast Track Designation with expanded access for BGC101. This designation signals significant regulatory validation for its lead product, BGC101, accelerating its path to market and indicating a strong potential for addressing unmet medical needs in microvascular diseases. For investors, this represents a critical de-risking event and a strong indicator of future commercial viability and strategic momentum.

Company Intelligence Q&A

What is BioGenCell's primary focus in cell therapy?

BioGenCell focuses on developing cellular therapies to treat blood flow problems in the limbs, a common side effect of diabetes and heart disease, utilizing autologous cells derived from patients themselves for self-repair.

When did BioGenCell secure its most recent funding round?

In May 2022, BioGenCell raised a $16 million Seed round led by Marius Nacht for microvascular disease treatment.

Has BioGenCell received any significant regulatory designations recently?

In December 2024, BioGenCell received FDA Fast Track Designation with expanded access for BGC101, its lead product for microvascular diseases treatment.

When was BioGenCell founded and by whom?

BioGenCell was founded in December 2008 by Yael Porat, Eyal Peleg, and Michael Belkin.

Has BioGenCell received any grants?

In May 2019, BioGenCell received a grant from the Service Public of Wallonia, DGO6.